Align Technology, Inc. (ALGN) EV/Sales Ratio: 2.88x
Is Align Technology, Inc.’s EV/Sales ratio high or low?
Align Technology, Inc.'s EV/Sales ratio of 2.88x is 51% below its 5-year average of 5.93x, near the low end of its 5-year range (2.09x–19.50x).
The EV/Sales ratio for Align Technology, Inc. (ALGN) is 2.88x as of Tuesday, June 9, 2026. It is above its 12-month average by 5.52% (2.73x).
ALGN EV/Sales Ratio Chart
ALGN Average EV/Sales Ratio Chart
ALGN Current vs Average EV/Sales Ratio Chart
ALGN EV/Sales Ratio Metrics
EV/SALES RATIO
2.88x
EV/SALES RATIO AVG TTM
2.73x
EV/SALES RATIO AVG 3Y
4.08x
EV/SALES RATIO AVG 5Y
5.93x
EV/SALES RATIO AVG 10Y
8.68x
EV/SALES RATIO AVG 15Y
7.56x
EV/SALES RATIO AVG 20Y
6.53x
CURRENT VS TTM AVG
+5.52%
CURRENT VS 3Y AVG
-29.36%
CURRENT VS 5Y AVG
-51.45%
CURRENT VS 10Y AVG
-66.81%
CURRENT VS 15Y AVG
-61.91%
CURRENT VS 20Y AVG
-55.93%
ALGN Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Align Technology, Inc. (ALGN) | — | 2.88x | 2.73x | 4.08x | 5.93x |
| Charles River Laboratories International, Inc. (CRL) | $9.14B | 3.02x | 2.79x | 3.02x | 3.80x |
| Hologic, Inc. (HOLX) | $16.97B | 4.25x | 4.02x | 4.39x | 4.15x |
| Bio-Rad Laboratories, Inc. (BIO) | $8.03B | 3.43x | 3.40x | 3.68x | 4.59x |
| Moderna, Inc. (MRNA) | $18.94B | 8.20x | 5.92x | 5.01x | 6.86x |
| Hims & Hers Health, Inc. (HIMS) | $6.46B | 3.18x | 4.77x | 4.20x | 4.29x |
| BioNTech SE (BNTX) | $21.87B | 4.37x | 5.19x | 4.38x | 4.12x |
| Mettler-Toledo International Inc. (MTD) | $23.50B | 6.30x | 7.35x | 7.52x | 8.18x |
| Waters Corporation (WAT) | $24.19B | 9.44x | 7.02x | 7.12x | 7.32x |
| Veeva Systems Inc. (VEEV) | $27.37B | 7.85x | 12.54x | 13.33x | 15.72x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
Align Technology, Inc. EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Align Technology, Inc. EV/Sales Ratio FAQ
- What is the EV/Sales ratio for Align Technology, Inc. (ALGN)?
- The EV/Sales ratio for ALGN stock is 2.88x.
- Is Align Technology, Inc.'s EV/Sales ratio high or low?
- Align Technology, Inc.'s EV/Sales ratio of 2.88x is 51% below its 5-year average of 5.93x, near the low end of its 5-year range (2.09x–19.50x).
- What is the TTM average EV/Sales ratio for Align Technology, Inc. (ALGN)?
- The TTM average EV/Sales ratio for ALGN stock is 2.73x.
- What is the 3Y average EV/Sales ratio for Align Technology, Inc. (ALGN)?
- The 3Y average EV/Sales ratio for ALGN stock is 4.08x.
- What is the 5Y average EV/Sales ratio for Align Technology, Inc. (ALGN)?
- The 5Y average EV/Sales ratio for ALGN stock is 5.93x.
- What is the 10Y average EV/Sales ratio for Align Technology, Inc. (ALGN)?
- The 10Y average EV/Sales ratio for ALGN stock is 8.68x.
- What is the 15Y average EV/Sales ratio for Align Technology, Inc. (ALGN)?
- The 15Y average EV/Sales ratio for ALGN stock is 7.56x.
- What is the 20Y average EV/Sales ratio for Align Technology, Inc. (ALGN)?
- The 20Y average EV/Sales ratio for ALGN stock is 6.53x.
Align Technology, Inc. EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-09 | 2.88x |
| 2026-06-08 | 2.77x |
| 2026-06-05 | 2.69x |
| 2026-06-04 | 2.70x |
| 2026-06-03 | 2.59x |
| 2026-06-02 | 2.68x |
| 2026-06-01 | 2.73x |
| 2026-05-29 | 2.82x |
| 2026-05-28 | 2.79x |
| 2026-05-27 | 2.61x |
| 2026-05-26 | 2.62x |
| 2026-05-22 | 2.62x |
| 2026-05-21 | 2.61x |
| 2026-05-20 | 2.62x |
| 2026-05-19 | 2.47x |
| 2026-05-18 | 2.54x |
| 2026-05-15 | 2.51x |
| 2026-05-14 | 2.57x |
| 2026-05-13 | 2.59x |
| 2026-05-12 | 2.66x |
| 2026-05-11 | 2.64x |
| 2026-05-08 | 2.71x |
| 2026-05-07 | 2.71x |
| 2026-05-06 | 2.80x |
| 2026-05-05 | 2.76x |
| 2026-05-04 | 2.82x |
| 2026-05-01 | 2.94x |
| 2026-04-30 | 2.89x |
| 2026-04-29 | 2.93x |
| 2026-04-28 | 2.91x |
| 2026-04-27 | 3.05x |
| 2026-04-24 | 3.13x |
| 2026-04-23 | 3.15x |
| 2026-04-22 | 3.25x |
| 2026-04-21 | 3.23x |
| 2026-04-20 | 3.17x |
| 2026-04-17 | 3.14x |
| 2026-04-16 | 3.05x |
| 2026-04-15 | 3.08x |
| 2026-04-14 | 3.05x |
| 2026-04-13 | 2.97x |
| 2026-04-10 | 2.84x |
| 2026-04-09 | 2.86x |
| 2026-04-08 | 2.91x |
| 2026-04-07 | 2.73x |
| 2026-04-06 | 2.82x |
| 2026-04-02 | 2.79x |
| 2026-04-01 | 2.83x |
| 2026-03-31 | 2.81x |
| 2026-03-30 | 2.72x |
| 2026-03-27 | 2.72x |
| 2026-03-26 | 2.91x |
| 2026-03-25 | 2.97x |
| 2026-03-24 | 2.95x |
| 2026-03-23 | 2.98x |
| 2026-03-20 | 2.84x |
| 2026-03-19 | 2.90x |
| 2026-03-18 | 2.83x |
| 2026-03-17 | 2.89x |
| 2026-03-16 | 2.77x |
| 2026-03-13 | 2.68x |
| 2026-03-12 | 2.73x |
| 2026-03-11 | 2.87x |
| 2026-03-10 | 2.77x |
| 2026-03-09 | 2.87x |
| 2026-03-06 | 2.86x |
| 2026-03-05 | 2.88x |
| 2026-03-04 | 3.00x |
| 2026-03-03 | 3.01x |
| 2026-03-02 | 3.12x |
| 2026-02-27 | 3.14x |
| 2026-02-26 | 3.22x |
| 2026-02-25 | 3.20x |
| 2026-02-24 | 3.15x |
| 2026-02-23 | 3.07x |
| 2026-02-20 | 3.23x |
| 2026-02-19 | 3.22x |
| 2026-02-18 | 3.25x |
| 2026-02-17 | 3.18x |
| 2026-02-13 | 3.17x |
| 2026-02-12 | 3.12x |
| 2026-02-11 | 3.37x |
| 2026-02-10 | 3.35x |
| 2026-02-09 | 3.28x |
| 2026-02-06 | 3.19x |
| 2026-02-05 | 2.97x |
| 2026-02-04 | 2.71x |
| 2026-02-03 | 2.63x |
| 2026-02-02 | 2.75x |
| 2026-01-30 | 2.74x |
| 2026-01-29 | 2.76x |
| 2026-01-28 | 2.78x |
| 2026-01-27 | 2.82x |
| 2026-01-26 | 2.83x |
| 2026-01-23 | 2.85x |
| 2026-01-22 | 2.85x |
| 2026-01-21 | 2.87x |
| 2026-01-20 | 2.79x |
| 2026-01-16 | 2.90x |
| 2026-01-15 | 2.90x |
| 2026-01-14 | 2.86x |
| 2026-01-13 | 2.87x |
| 2026-01-12 | 2.91x |
| 2026-01-09 | 2.92x |
| 2026-01-08 | 2.88x |
| 2026-01-07 | 2.81x |
| 2026-01-06 | 2.83x |
| 2026-01-05 | 2.69x |
| 2026-01-02 | 2.62x |
| 2025-12-31 | 2.62x |
| 2025-12-30 | 2.65x |
| 2025-12-29 | 2.65x |
| 2025-12-26 | 2.66x |
| 2025-12-24 | 2.65x |
| 2025-12-23 | 2.63x |
| 2025-12-22 | 2.67x |
| 2025-12-19 | 2.65x |
| 2025-12-18 | 2.71x |
| 2025-12-17 | 2.70x |
| 2025-12-16 | 2.74x |
| 2025-12-15 | 2.74x |
| 2025-12-12 | 2.79x |
| 2025-12-11 | 2.76x |
| 2025-12-10 | 2.77x |
| 2025-12-09 | 2.67x |
| 2025-12-08 | 2.65x |
| 2025-12-05 | 2.64x |
| 2025-12-04 | 2.63x |
| 2025-12-03 | 2.60x |
| 2025-12-02 | 2.52x |
| 2025-12-01 | 2.45x |
| 2025-11-28 | 2.45x |
| 2025-11-26 | 2.46x |
| 2025-11-25 | 2.46x |
| 2025-11-24 | 2.39x |
| 2025-11-21 | 2.37x |
| 2025-11-20 | 2.19x |
| 2025-11-19 | 2.21x |
| 2025-11-18 | 2.18x |
| 2025-11-17 | 2.19x |
| 2025-11-14 | 2.27x |
| 2025-11-13 | 2.31x |
| 2025-11-12 | 2.35x |
| 2025-11-11 | 2.41x |
| 2025-11-10 | 2.29x |
| 2025-11-07 | 2.23x |
| 2025-11-06 | 2.21x |
| 2025-11-05 | 2.27x |
| 2025-11-04 | 2.29x |
| 2025-11-03 | 2.34x |
| 2025-10-31 | 2.33x |
| 2025-10-30 | 2.34x |
| 2025-10-29 | 2.22x |
| 2025-10-28 | 2.24x |
| 2025-10-27 | 2.29x |
| 2025-10-24 | 2.28x |
| 2025-10-23 | 2.29x |
| 2025-10-22 | 2.29x |
| 2025-10-21 | 2.30x |
| 2025-10-20 | 2.27x |
| 2025-10-17 | 2.19x |
| 2025-10-16 | 2.18x |
| 2025-10-15 | 2.16x |
| 2025-10-14 | 2.18x |
| 2025-10-13 | 2.18x |
| 2025-10-10 | 2.11x |
| 2025-10-09 | 2.22x |
| 2025-10-08 | 2.24x |
| 2025-10-07 | 2.19x |
| 2025-10-06 | 2.21x |
| 2025-10-03 | 2.22x |
| 2025-10-02 | 2.16x |
| 2025-10-01 | 2.14x |
| 2025-09-30 | 2.10x |
| 2025-09-29 | 2.12x |
| 2025-09-26 | 2.11x |
| 2025-09-25 | 2.09x |
| 2025-09-24 | 2.15x |
| 2025-09-23 | 2.17x |
| 2025-09-22 | 2.21x |
| 2025-09-19 | 2.21x |
| 2025-09-18 | 2.23x |
| 2025-09-17 | 2.17x |
| 2025-09-16 | 2.22x |
| 2025-09-15 | 2.20x |
| 2025-09-12 | 2.21x |
| 2025-09-11 | 2.29x |
| 2025-09-10 | 2.24x |
| 2025-09-09 | 2.29x |
| 2025-09-08 | 2.31x |
| 2025-09-05 | 2.35x |
| 2025-09-04 | 2.27x |
| 2025-09-03 | 2.23x |
| 2025-09-02 | 2.32x |
| 2025-08-29 | 2.40x |
| 2025-08-28 | 2.39x |
| 2025-08-27 | 2.40x |
| 2025-08-26 | 2.40x |
| 2025-08-25 | 2.46x |
| 2025-08-22 | 2.54x |
| 2025-08-21 | 2.38x |
| 2025-08-20 | 2.43x |
| 2025-08-19 | 2.44x |
| 2025-08-18 | 2.46x |
| 2025-08-15 | 2.41x |
| 2025-08-14 | 2.42x |
| 2025-08-13 | 2.47x |
| 2025-08-12 | 2.38x |
| 2025-08-11 | 2.27x |
| 2025-08-08 | 2.36x |
| 2025-08-07 | 2.34x |
| 2025-08-06 | 2.31x |
| 2025-08-05 | 2.39x |
| 2025-08-04 | 2.36x |
| 2025-08-01 | 2.34x |
| 2025-07-31 | 2.20x |
| 2025-07-30 | 3.57x |
| 2025-07-29 | 3.62x |
| 2025-07-28 | 3.64x |
| 2025-07-25 | 3.61x |
| 2025-07-24 | 3.55x |
| 2025-07-23 | 3.59x |
| 2025-07-22 | 3.40x |
| 2025-07-21 | 3.31x |
| 2025-07-18 | 3.34x |
| 2025-07-17 | 3.37x |
| 2025-07-16 | 3.33x |
| 2025-07-15 | 3.38x |
| 2025-07-14 | 3.50x |
| 2025-07-11 | 3.55x |
| 2025-07-10 | 3.59x |
| 2025-07-09 | 3.52x |
| 2025-07-08 | 3.43x |
| 2025-07-07 | 3.39x |
| 2025-07-03 | 3.45x |
| 2025-07-02 | 3.45x |
| 2025-07-01 | 3.40x |
| 2025-06-30 | 3.31x |
| 2025-06-27 | 3.30x |
| 2025-06-26 | 3.28x |
| 2025-06-25 | 3.27x |
| 2025-06-24 | 3.26x |
| 2025-06-23 | 3.20x |
| 2025-06-20 | 3.17x |
| 2025-06-18 | 3.14x |
| 2025-06-17 | 3.05x |
| 2025-06-16 | 3.19x |
| 2025-06-13 | 3.10x |
| 2025-06-12 | 3.17x |
| 2025-06-11 | 3.24x |
| 2025-06-10 | 3.29x |
| 2025-06-09 | 3.16x |
| 2025-06-06 | 3.15x |
| 2025-06-05 | 3.14x |
| 2025-06-04 | 3.14x |
| 2025-06-03 | 3.12x |
| 2025-06-02 | 3.11x |
| 2025-05-30 | 3.16x |
| 2025-05-29 | 3.20x |
| 2025-05-28 | 3.14x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Align Technology, Inc.
Align Technology, Inc. is a medical technology enterprise that develops, produces, and markets its leading products: Invisalign transparent dental aligners and iTero digital intraoral scanners, along with related services. These offerings serve a wide range of dental professionals, including orthodontists, general dentists, and those specializing in restorative and cosmetic dentistry. The company's operations are divided into two main business units: "Clear Aligner" and "Scanners and Services." The Clear Aligner segment offers a variety of solutions. Its comprehensive products include the full Invisalign treatment for teenage patients, designed to address complex orthodontic needs such as mandibular advancement, patient compliance tracking, and managing tooth eruption. It also features specialized Invisalign First Phase I and Phase 2 packages for younger children, typically aged seven to ten, who have mixed dentition (a combination of primary and permanent teeth). Beyond these, the segment provides non-comprehensive aligner options like Invisalign moderate, lite, express, and Invisalign Go. Additional non-case products include retention devices, fees for Invisalign training, and sales of ancillary items such as cleaning materials and adjustment tools used by dental practitioners during treatment. The Scanners and Services segment centers around the iTero scanner, a unified hardware platform offering various software applications for both restorative and orthodontic procedures. It supplies specialized restorative software to general dentists, prosthodontists, periodontists, and oral surgeons, as well as distinct software for orthodontists to manage digital patient records, perform diagnoses, and facilitate the fabrication of printed models and retainers. This segment also provides computer-aided design and manufacturing (CAD/CAM) services, along with supplementary products like disposable covers for the scanner wand and iTero models and dies. Furthermore, it includes third-party scanners and digital scan solutions, the Invisalign Outcome Simulator (a chair-side and cloud-based application for the iTero scanner), the Invisalign Progress Assessment tool, and TimeLapse technology, which enables clinicians to compare a patient's historical 3D scans against current data. Align Technology distributes its products worldwide, with a strong presence in the United States, Switzerland, and China. Founded in 1997, the company is headquartered in Tempe, Arizona.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Joseph Hogan